Drugs fall from dizzy heights, but investors should stand by science

Despite patent problems, there are opportunities in healthcare stocks, writes Simon Hildrey

Three years ago, pharmaceutical companies appeared to offer healthy solutions for investors. But ever since the technology bubble burst, healthcare has struggled to produce anything approaching vigorous returns.

Three years ago, pharmaceutical companies appeared to offer healthy solutions for investors. But ever since the technology bubble burst, healthcare has struggled to produce anything approaching vigorous returns.

In 2000, the sector was a top performer, with one of the biggest drugs companies, GlaxoSmithKline, comprising more than 10 per cent of the FTSE 100. In a society with an ageing population, requiring more medical treatment – particularly drugs – this growth seemed likely to continue. What appeared to be an endless supply of medicines was coming on to the market, and pharmaceutical companies looked certain to benefit.

But the sector fell in value during 2001 and 2002, the first time in the past two decades that it has declined in consecutive years. And in the past 12 months, according to the ratings agency Standard & Poor's, the sector has fallen again, this time by 36 per cent.

In the past year, among healthcare funds, First State Global Health & Biotechnology has fallen by 34.09 per cent, Framlington Biotechnology by 49.6 per cent, Framlington Health by 42.68 per cent, M&G Global Health Care by 30.83 per cent and Schroder Medical Discovery by 30.78 per cent. This compares with declines of 25.03 per cent in the FTSE All Share and 29.21 per cent in the S&P 500.

Pharmaceutical stocks have been hit by the expiry of an increasing number of patents, by successful court challenges to other patents by generic companies, and by a slowdown in the development of new drugs. Pharmaceutical companies are also coming under pressure to offer drugs at cheaper prices to the developing world.

Patents are vital to the drugs firms. They last 17 years but start from when they are registered – usually when the drug is first developed in the laboratory – not from when they come to market. This means pharmaceutical groups have between 10 and 12 years to make money from their exclusivity.

It has been estimated that in 2002, drugs with sales totalling $8.5bn (£5.4bn) saw their patents expire. This figure is expected to rise to $18.4bn in 2003, then fall to $15.2bn in 2004 and $10.5bn in 2005. It expected to rise again in 2006 when one drug alone, Merck's cholesterol drug Zocor, worth $5bn, will come to the end of its patent.

This situation has been exacerbated by the increasingly aggressive challenges being issued in court by generic companies. It has been estimated that 75 per cent of these challenges are successful and that 11 blockbuster drugs with annual sales of $15bn currently face patent attacks. GlaxoSmithKline, for example, has two patents being challenged, according to Joe Anderson, head of global health and biotechnology at First State Investments.

Successful challenges to patents have had a dramatic effect on the sales of big pharmaceutical companies and have increased the risk of investing in the sector. Caspar Rock, part of the healthcare team at Framlington, says sales of branded drugs can decline 90 per cent in the first 90 days after the end of a patent.

Mr Rock adds that patients in the US are being encouraged to use cheaper generic drugs rather than branded ones by the four big pharmacy benefit managers, who manage prescription drug benefit programmes for employers, unions and health insurers. This is affecting margins and sales of branded drugs.

But this gloomy picture does not mean investors should ignore the healthcare sector. Of course, as Robert Burdett, co-head of Credit Suisse Asset Management's multi-manager service, says, many will already have healthcare investments without even knowing it, because mainstream funds have significant exposures to the sector. Healthcare stocks make up 14.5 per cent of the S&P 500 index, 10.5 per cent of the FTSE All Share and 10 per cent of Europe excluding the UK.

Mr Anderson at First State Investments argues that there is still strong demand for the sector. "The population is ageing, and as we get older we spend more money on healthcare," he says. "It has been estimated that 80 per cent of what we spend on healthcare in our lifetime is spent in the last year of our life."

Healthcare comprises more than simply big pharmaceutical companies. Samuel Isaly, manager of the Close Finsbury Pharmaceutical fund, points to three sub-sectors: biotechnology, medical devices and health services.

"Biotechnology stocks are higher-risk investments than big pharmaceutical companies," he says, "but they offer the potential of higher returns. They are not as vulnerable to patent challenges because protein is not as easy to replicate as chemical pills. We have identified 50 biotechnology stocks that are either profitable or will be by 2006."

Biotechnology firms are also offering licensing agreements to pharmaceutical companies to distribute their drugs, so increasing their revenue.

When deciding whether to invest in the sector, investors should analyse the quality of the company's management and cashflow, as well as determining the number of new drugs in the pipeline and the number of patents being challenged. A managed fund is often the simplest way in, and tends to be less risky than investing directly in individual companies.

Disease crisis in developing world

* Aids will kill 46 million people this decade in the 53 worst-affected countries, according to the United Nations Population Division. This figure is forecast to rise to 278 million by 2050.

* HIV/Aids infection rates are greater than 30 per cent in a number of African countries, including Botswana, Lesotho and Zimbabwe.

* Tuberculosis (TB) kills approximately two million people each year. It is estimated that between 2002 and 2020, approximately one billion people will be newly infected, more than 150 million will get sick, and 36 million will die if more is not done to bring the disease under control.

* Malaria is the cause of 300 million acute illnesses and around a million deaths each year. There is increased resistance to existing treatments.

* Twelve infectious diseases account for 20 per cent of the world's global disease burden.

Source: ISIS

Independent Partners; Do you need financial advice on your investments, pension or insurance? Book a free consultation with an independent Financial Adviser at VouchedFor.co.uk

Finacial products from our partners
Property search
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

ES Rentals

    iJobs Job Widget
    iJobs Money & Business

    Neil Pavier: Commercial Analyst

    £50,000 - £55,000: Neil Pavier: Are you a professionally qualified commercial ...

    Loren Hughes: Financial Accountant

    £45,000 - £55,000: Loren Hughes: Are you looking for a new opportunity that wi...

    Sheridan Maine: Finance Analyst

    Circa £45,000-£50,000 + benefits: Sheridan Maine: Are you a newly qualified ac...

    Sheridan Maine: Financial Accountant

    £150 - £190 Daily Rate: Sheridan Maine: One of London's leading water supplier...

    Day In a Page

    No postcode? No vote

    Floating voters

    How living on a houseboat meant I didn't officially 'exist'
    Louis Theroux's affable Englishman routine begins to wear thin

    By Reason of Insanity

    Louis Theroux's affable Englishman routine begins to wear thin
    Power dressing is back – but no shoulderpads!

    Power dressing is back

    But banish all thoughts of Eighties shoulderpads
    Spanish stone-age cave paintings 'under threat' after being re-opened to the public

    Spanish stone-age cave paintings in Altamira 'under threat'

    Caves were re-opened to the public
    'I was the bookies’ favourite to be first to leave the Cabinet'

    Vince Cable interview

    'I was the bookies’ favourite to be first to leave the Cabinet'
    Election 2015: How many of the Government's coalition agreement promises have been kept?

    Promises, promises

    But how many coalition agreement pledges have been kept?
    The Gaza fisherman who built his own reef - and was shot dead there by an Israeli gunboat

    The death of a Gaza fisherman

    He built his own reef, and was fatally shot there by an Israeli gunboat
    Saudi Arabia's airstrikes in Yemen are fuelling the Gulf's fire

    Saudi airstrikes are fuelling the Gulf's fire

    Arab intervention in Yemen risks entrenching Sunni-Shia divide and handing a victory to Isis, says Patrick Cockburn
    Zayn Malik's departure from One Direction shows the perils of fame in the age of social media

    The only direction Zayn could go

    We wince at the anguish of One Direction's fans, but Malik's departure shows the perils of fame in the age of social media
    Young Magician of the Year 2015: Meet the schoolgirl from Newcastle who has her heart set on being the competition's first female winner

    Spells like teen spirit

    A 16-year-old from Newcastle has set her heart on being the first female to win Young Magician of the Year. Jonathan Owen meets her
    Jonathan Anderson: If fashion is a cycle, this young man knows just how to ride it

    If fashion is a cycle, this young man knows just how to ride it

    British designer Jonathan Anderson is putting his stamp on venerable house Loewe
    Number plates scheme could provide a licence to offend in the land of the free

    Licence to offend in the land of the free

    Cash-strapped states have hit on a way of making money out of drivers that may be in collision with the First Amendment, says Rupert Cornwell
    From farm to fork: Meet the Cornish fishermen, vegetable-growers and butchers causing a stir in London's top restaurants

    From farm to fork in Cornwall

    One man is bringing together Cornwall's most accomplished growers, fishermen and butchers with London's best chefs to put the finest, freshest produce on the plates of some of the country’s best restaurants
    Robert Parker interview: The world's top wine critic on tasting 10,000 bottles a year, absurd drinking notes and New World wannabes

    Robert Parker interview

    The world's top wine critic on tasting 10,000 bottles a year, absurd drinking notes and New World wannabes
    Don't believe the stereotype - or should you?

    Don't believe the stereotype - or should you?

    We exaggerate regional traits and turn them into jokes - and those on the receiving end are in on it too, says DJ Taylor